Strategically located in Seoul, the new site will provide local, regional and global pharmaceutical and biotech companies with a one-stop service for clinical supplies − from cGMP storage,
A pre-defined number of patients demonstrated clinical benefit per protocol to allow the clinical trial to advance to the second and final stage of the trial (Stage 2).
The NDA represents the first potential treatment for pediatric patients with sickle cell disease, and the first potential new treatment in nearly 20 years for adult patients. Emmaus
The funding parties will provide $4 million over two years to fund research and development of AnTolRx's antigen-specific Targeted Nanoparticle Tolerance Therapeutics (TNTT) to treat immune disorders including
ImmuPharma has been requested to open a new site in Mauritius to participate in the current pivotal Phase III Lupuzor trial. Cap Research, a leading contract research organisation in
TIDES will enroll approximately 20,000 healthy children between the ages of four and 16 years living in dengue-endemic countries in Latin America and Asia. The study willevaluate the
With this approval, ORENCIA is the first biologic therapy with an indication in the European Union (EU) specifically applicable to the treatment of MTX-naive RA patients with highly
Under the terms of the agreement, about 210 Avlon employees will remain employed at the site, and the plant will continue to manufacture critical AstraZeneca pharmaceutical products on
Rhopressa is a novel once-daily eye drop designed to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The filing includes the results of the first two
As previously reported, first-in-human studies for the Porcupine inhibitor are expected to commence in the first quarter of 2017. The novel, potent small molecule Porcupine inhibitor targets the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.